NEUROGENE INC (NGNE)
US64135M1053 - Common Stock
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ: NGNE). Such investors...
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
Which stocks are experiencing notable movement on Monday?
Top movers analysis one hour before the close of the markets on 2024-11-18: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Top movers in Monday's session
Oversold Conditions For Neurogene (NGNE)
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug
The company is now scrapping a high dose of its Rett syndrome drug after a patient experienced a serious side effect.
Which stocks are moving before the opening bell on Monday?
Top movers in Monday's pre-market session
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Notable Tuesday Option Activity: NGNE, VKTX, AVDL
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Let's take a look at the stocks that are in motion in today's session.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Which stocks are gapping on Tuesday?
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect
Neurogene tested its gene therapy in female patients with Rett syndrome.
What's going on in today's pre-market session
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Get insights into the top gainers and losers of Monday's after-hours session.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Monday's session: top gainers and losers
What's going on in today's session
Let's have a look at the top gainers and losers in the middle of the day of today's session.
These stocks are gapping in today's session
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.
These stocks are moving in today's pre-market session
Stay updated with the stocks that are on the move in Monday's pre-market session.
Neurogene Announces Oversubscribed $200 Million Private Placement
Noteworthy Wednesday Option Activity: WING, NGNE, VICR
Commit To Purchase Neurogene At $25, Earn 16% Using Options
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024
NGNE stock results show that Neurogene missed analyst estimates for earnings per share the second quarter of 2024.
NGNE Stock Earnings: Neurogene Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Neurogene (NASDAQ:NGNE) just reported results for the second quarter of 2024.Ne...
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome
Neurogene to Participate in BMO Genetic Medicines Summit
Neurogene Announces Addition to Russell 3000® Index
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene to Participate in Upcoming Conferences
Neurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot Program
Neurogene Becomes Oversold (NGNE)
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Neurogene (NASDAQ:NGNE) just reported results for the first quarter of 2024.Neu...
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024
NGNE stock results show that Neurogene beat analyst estimates for earnings per share the first quarter of 2024.